UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

~~SECURITIES AND EXCHANGE COMMISSION~~_______________________________________________________

Washington, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

~~March~~September 1126, ~~2015~~2016

~~MULTICELL TECHNOLOGIES, INC.~~_______________________________________________________

MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter)

Delaware		001-10221		52-1412493
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Delaware
(State or other jurisdiction of incorporation)

68 Cumberland Street, Suite 301 Woonsocket, Rhode Island 02895 (Address of principal executive offices, including zip code)

~~Woonsocket~~(401) 762-0045 (Registrant’s telephone number, including ~~Island~~area ~~02895~~code)

N/A (~~Address~~Former ofname ~~principal~~or ~~executive~~former ~~offices~~address, if changed ~~including~~since ~~zip~~last ~~code~~report)

(401) 762-0045

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

¨ [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

¨ [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 58.~~07.~~01 ~~Submission~~Other ~~of Matters to a Vote of Security Holders.~~Events

~~MultiCell~~On ~~Technologies, Inc.~~September ~~(the “Company”) held its Annual Meeting of Stockholders on March 11~~26, ~~2015~~2016, at the ~~offices~~Company’s ofmajority ~~Procopio,~~owned ~~Cory~~subsidiary, ~~Hargreaves~~ &MultiCell ~~Savitch LLP~~Immunotherapeutics, ~~One~~Inc. ~~Del Mar~~(MCIT), ~~12544~~released ~~High~~a ~~Bluff~~presentation ~~Drive,~~concerning its ~~Suite~~therapeutic ~~300,~~development ~~San~~platform ~~Diego, California 92130, to consider and vote on~~ (the ~~matters listed~~“MCIT ~~below~~Presentation”). The ~~proposals are described in detail in the Proxy Statement on Schedule 14A filed by the Company with the Securities~~MCIT ~~and~~Presentation ~~Exchange~~is ~~Commission~~furnished onas ~~December~~Exhibit ~~12, 2014~~99.1 ~~The~~to ~~final~~this ~~voting~~Current ~~results~~Report ~~from~~on ~~the~~Form ~~meeting are set forth below~~8-K.

~~Proposal~~The 1:MCIT ~~Election~~presentation and the information therein shall not be deemed to be “filed” for purposes of ~~Directors~~Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

~~This~~Exhibit ~~proposal~~No. ~~was~~99.1 ~~to elect~~The ~~directors~~MCIT toPresentation ~~serve~~by ~~for~~MultiCell ~~the~~Immunotherapeutics, ~~ensuing year and until their successors are elected~~Inc. ~~Based~~was released on ~~the~~September ~~following votes~~26, ~~the individuals named below were each elected to serve as directors until the Company’s next annual meeting of stockholders~~2016.

Name	Votes For	Votes Withheld	Broker Non-Votes
W. Gerald Newmin	760,163,035	139,542,195
Thomas A. Page	771,163,049	128,542,181
Edward Sigmond	767,610,977	132,094,253
Stephen Chang, Ph. D.	831,730,289	67,974,941
Grant Miller	771,173,508	128,531,722

Proposal 2: Ratification of Selection of Independent Auditors

The proposal ratifies the selection of Eide Bailly, LLP as the Company’s independent registered public accounting firm. The results of the voting included 2,792,701,382 votes for, 246,531,270 votes against, 102,535,500 votes abstained and no broker non-votes. The selection was ratified.

Proposal 3: Approval of the Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation

The proposal was to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Restated Certificate”), to increase the number of authorized shares of the Company’s common stock to a total of 10.0 billion shares. The results of the voting included 2,271,617,094 votes for, 762,110,830 votes against, 108,040,228 votes abstained and no broker non-votes. The Certificate of Amendment to the Restated Certificate was approved.

Proposal 4: Approval of the Company’s 2014 Equity Incentive Plan

This proposal was to approve the Company’s 2014 Equity Incentive Plan (the “Plan”). The results of the voting included 569,733,952 votes for, 233,832,900 votes against, 96,138,378 votes abstained and no broker non-votes. The Plan was approved.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MULTICELL TECHNOLOGIES, INC. ~~By: /s/ W. Gerald Newmin W. Gerald NewminChief Executive Officer, Chief Financial Officer~~

~~Date:~~W. ~~March~~Gerald 13Newmin Chief Executive Officer, ~~2015~~Chief Financial Officer

Date: September 26, 2016

Filing Compare · MultiCell Technologies, Inc.